Skip to main content
Download PDF

Practical solutions for hypertensive patients with dyslipidemia

Artery Research volume 18, pages 49–54 (2017)Cite this article

Abstract

Arterial hypertension and dyslipidemia often coexist and constitute major risk factors of ischemic heart disease. Aggressive treatment of both comorbidities is of paramount importance to decrease global risk. Low adherence is a determinant of poor risk factor control and increases adverse cardiovascular outcomes. Regarding treatment of hypertension, combination therapy is superior in achieving target BP values compared to up-titrating monotherapy and it is recommended in hypertension guidelines. The combined use of drugs in a single pill formulation increases adherence and reduces cardiovascular risk. Our review of the literature indicates that triple therapy with an angiotensin converting enzyme inhibitor, a calcium channel blocker and a statin is associated with a significant reduction in major cardiovascular events. This is attributed to synergy at the vascular, and is translated into efficacy at the clinical level.

References

  1. World Heart Organization. Global atlas on cardiovascular disease prevention and control. WHO Press; 2011.

  2. Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165(10):1147–52.

    Google Scholar 

  3. Thoenes M, Bramlage P, Zhong S, Shang S, Volpe M, Spirk D. Hypertension control and cardiometabolic risk: a regional perspective. Cardiol Res Pract 2012;2012. 925046.

  4. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet 2005;365(9457):434–41.

    Google Scholar 

  5. Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, Böhm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens 2010;24(5):336–44.

    Google Scholar 

  6. Gyberg V, Kotseva K, Dallongeville J, Backer GD, Mellbin L, Rydén L, et al., EUROASPIRE Study Group. Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfill guideline recommended targets? A report from the EUROASPIRE III cross-sectional study. Eur J Prev Cardiol 2015;22(6):753–61.

    Google Scholar 

  7. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: metaanalysis on 11,000 participants from 42 trials. Am J Med 2009; 122(3):290–300.

    Google Scholar 

  8. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012;33(16): 2088–97.

    Google Scholar 

  9. Cheng J, Zhang W, Zhang X, Han F, Li X, He X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 2014;174(5): 773–85.

    Google Scholar 

  10. Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005;46(2):386–92.

    Google Scholar 

  11. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359(23):2417–28.

    Google Scholar 

  12. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489):895–906.

    Google Scholar 

  13. Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011 Feb; 124(2):128–35.

    Google Scholar 

  14. Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN, et al., GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004;18(11):781–8.

    Google Scholar 

  15. Bertrand ME, Ferrari R, Remme WJ, Simoons ML, Deckers JW, Fox KM, EUROPA Investigators. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J 2010; 159(5):795–802.

    Google Scholar 

  16. Bertrand ME, Vlachopoulos C, Mourad JJ. Triple combination therapy for global cardiovascular risk: atorvastatin, perindopril, and amlodipine. Am J Cardiovasc Drugs 2016;16(4): 241–53.

    Google Scholar 

  17. Sever P, Dahlo¨f B, Poulter N, Wedel H, Beevers G, Caulfield M, et al., ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian cardiac outcomes trial. Eur Heart J 2006; 27(24):2982–8.

    Google Scholar 

  18. Ferrari R. Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine. Curr Med Res Opin 2008;24(12):3543–57.

    Google Scholar 

  19. Rubba P. Effects of atorvastatin on the different phases of atherogenesis. Drugs 2007;67(Suppl. 1):17–27.

    Google Scholar 

  20. Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis 2002 Dec;165(2):191–9.

    Google Scholar 

  21. Vlachopoulos C, Aznaouridis K, Dagre A, Vasiliadou C, Masoura C, Stefanadi E, et al. Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects. Eur Heart J 2007;28(17):2102–9.

    Google Scholar 

  22. Ceconi C, Francolini G, Bastianon D, Gitti GL, Comini L, Ferrari R. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther 2007;21(6): 423–9.

    Google Scholar 

  23. Vlachopoulos C, Aznaouridis K, O’Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010;31(15):1865–71.

    Google Scholar 

  24. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318–27.

    Google Scholar 

  25. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al., CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113(9):1213–25.

    Google Scholar 

  26. Nichols WW, O’Rourke MF, Vlachopoulos C. McDonald’s blood flow in arteries: theoretic, experimental and clinical principles. 6th ed. London, UK: Edward Arnold; 2011.

  27. Vlachopoulos C, Terentes-Printzios D, Tousoulis D. The phar-macodynamics of arterial stiffness. In: Laurent S, Cockcroft J, editors. Central aortic blood pressure. Paris, France: Servier; 2015.

  28. Shahin Y, Khan JA, Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis 2012;221:18–33.

    Google Scholar 

  29. Böhm M, Schumacher H, Laufs U, Sleight P, Schmieder R, Unger T, et al. Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J 2013;166(2):306–14.

    Google Scholar 

  30. Vlachopoulos C, Xaplanteris P. What is the role of combination therapy in treating hypertension? Dialogues Cardiovasc Med 2015;20:15–23.

    Google Scholar 

  31. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120(8):713–9.

    Google Scholar 

  32. Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014;348:g3318.

  33. Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34(38):2940–8.

    Google Scholar 

  34. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016 Oct 14;37(39):2999–3058 [Epub 2016 Aug 27].

  35. Emberson J, Whincup P, Morris R, Walker M, Ebrahim S. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004;25(6):484–91.

    Google Scholar 

  36. Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, et al., HOPE3 Investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016;374(21):2032–43.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension Unit and Cardiometabolic Syndrome Unit, 1st Department of Cardiology, Athens Medical School, Hippokration Hospital, ProfitiElia 24, 14575, Athens, Greece

    Charalambos Vlachopoulos & Nikolaos Ioakeimidis

Authors
  1. Charalambos Vlachopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nikolaos Ioakeimidis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charalambos Vlachopoulos.

Additional information

This article was presented as lecture in the symposium on “Protecting arteries against hypertension and dyslipidemia” at the ARTERY 16 Congress in Copenhagen, Denmark (October 13–15, 2016).

Rights and permissions

This is an open access article distributed under the CC BY-NC license. https://doi.org/creativecommons.org/licenses/by/4.0/

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vlachopoulos, C., Ioakeimidis, N. Practical solutions for hypertensive patients with dyslipidemia. Artery Res 18, 49–54 (2017). https://doi.org/10.1016/j.artres.2017.03.002

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.artres.2017.03.002

Keywords

Artery Research

ISSN: 1876-4401

Contact us